Research progress of small-molecule natural medicines for the treatment of ischemic stroke  

作　　者：Kui Liu Ling Wang Tao Pang 

机构地区：[1]State Key Laboratory of Natural Medicines,New Drug Screening and Pharmacodynamics Evaluation Center,China Pharmaceutical University,Nanjing 210009,China

出　　处：《Chinese Journal of Natural Medicines》2025年第1期21-30,共10页中国天然药物(英文版)

基　　金：supported by the National Natural Science Foundation of China(Nos.82174010 and 81973512)。

摘　　要：Stroke is the second leading cause of disability and mortality worldwide,imposing a substantial socioeconomic burden on individuals and healthcare systems.Annually,approximately 14 million people experience stroke,with ischemic stroke comprising nearly 85%of cases,of which 10%to 20%involve large vessel occlusions.Currently,recombinant tissue plasminogen activator(tPA)remains the only approved pharmacological intervention.However,its utility is limited due to a narrow therapeutic window and low recanalization rates,making it applicable to only a minority of patients.Therefore,there is an urgent need for novel therapeutic strategies,including pharmacological advancements and combinatory treatments.Small-molecule natural medicines,particularly those derived from traditional Chinese herbs,have demonstrated significant therapeutic potential in ischemic stroke management.These compounds exert multiple neuroprotective effects,such as antioxidation,anti-inflammatory action,and inhibition of apoptosis,all of which are critical in mitigating stroke-induced cerebral damage.This review comprehensively examines the pathophysiology of acute ischemic stroke(AIS)and highlights the recent progress in the development of small-molecule natural medicines as promising therapeutic agents for cerebral ischemic stroke.

关 键 词：Natural medicines Small molecule Ischemic stroke ANTIOXIDANTS NEUROINFLAMMATION 

分 类 号：R277.7[医药卫生—中医学]